Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024
| dc.contributor.author | Costa, Paula | |
| dc.contributor.author | Advinha, Ana Margarida | |
| dc.contributor.author | Oliveira-Martins, Sofia | |
| dc.date.accessioned | 2026-02-13T15:24:57Z | |
| dc.date.available | 2026-02-13T15:24:57Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Managed Entry Agreements (MEAs) are tools designed to reduce clinical uncertainty and mitigate budget impact of often high-cost, innovative medicines. While finance-based MEAs have been widely used, the increasing complexity of therapies has driven the adoption of more sophisticated and tailored agreements, including risk-sharing models. This study aims to characterize the MEAs established to support public coverage decisions for innovative medicines—defined as those containing new active substances—that received marketing authorization between 2014 and 2024 and obtained positive reimbursement decisions in Portugal. | por |
| dc.identifier.authoremail | nd | |
| dc.identifier.authoremail | nd | |
| dc.identifier.authoremail | nd | |
| dc.identifier.citation | Costa, P, Advinha AM, Oliveira-Martins S. Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024. In: Abstracts of the ISPOR Europe 2025. Glasgow, Scotland: Value in Health, 28(S2); 2025. HPR125. | por |
| dc.identifier.doi | https://doi.org/10.1016/j.jval.2025.09.1532 | por |
| dc.identifier.uri | https://www.valueinhealthjournal.com/article/S1098-3015(25)04089-6/abstract?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301525040896%3Fshowall%3Dtrue | |
| dc.identifier.uri | http://hdl.handle.net/10174/41160 | |
| dc.language.iso | por | por |
| dc.peerreviewed | no | por |
| dc.rights | openAccess | por |
| dc.title | Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024 | por |
| dc.type | article |